CD4 and tuberculosis: Heterologous prime-boost and recombinant protein anti-TB vaccine models have shown that the vaccine-induced IL-2-secreting CD4+ T cell subsets could maintain the IL-2-producing ability for at least 26 weeks post challenge infection and were associated with enhanced control of bacterial growth in mouse models (42, 43).